Edition:
United Kingdom

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

40.39USD
22 Oct 2018
Change (% chg)

$-1.79 (-4.24%)
Prev Close
$42.18
Open
$42.36
Day's High
$42.94
Day's Low
$39.62
Volume
215,499
Avg. Vol
231,498
52-wk High
$136.90
52-wk Low
$39.62

Latest Key Developments (Source: Significant Developments)

Puma Biotechnology Announces Results Of CHMP Reexamination Of MAA For Neratinib
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY ANNOUNCES RESULTS OF CHMP REEXAMINATION OF MAA FOR NERATINIB FOR EXTENDED ADJUVANT TREATMENT OF HER2-POSITIVE EARLY STAGE BREAST CANCER.PUMA BIOTECHNOLOGY - EUROPEAN MEDICINES AGENCY HAS ADOPTED A POSITIVE TREND VOTE RECOMMENDING APPROVAL OF MAA FOR NERATINIB.PUMA BIOTECHNOLOGY - DECISION FOLLOWS REEXAMINATION OF NEGATIVE OPINION ANNOUNCED BY CHMP AT FORMAL MEETING WITH CO TO DISCUSS MAA ON FEB 23, 2018.  Full Article

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS.PUMA BIOTECHNOLOGY - EUROPEAN PATENT OFFICE HAS UPHELD CLAIMS IN PUMA'S LICENSED EUROPEAN PATENT, EP 2416774, WHICH WERE BEING OPPOSED BY HEXAL AG.  Full Article

PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA.PUMA BIOTECHNOLOGY INC - ‍PUMA WILL RECEIVE UPFRONT AND MILESTONE PAYMENTS OF UP TO $4.5 MILLION THROUGHOUT TERM OF THE AGREEMENT​.PUMA BIOTECHNOLOGY-SPECIALISED THERAPEUTICS RESPONSIBLE FOR SEEKING REGULATORY APPROVALS, FOR COMMERCIALIZING NERLYNX IN SOUTH EAST ASIAN COUNTRIES.PUMA BIOTECHNOLOGY INC - ‍EXPECT TO HAVE REGULATORY APPROVAL FOR NERLYNX IN AUSTRALIA BY Q2 OF 2019​.  Full Article

Puma Biotechnology reports Q3 adj. loss per share $1.36
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Puma Biotechnology Inc :Puma Biotechnology reports third quarter 2017 financial results.Q3 adjusted non-GAAP loss per share $1.36.Q3 earnings per share view $-2.58 -- Thomson Reuters I/B/E/S.Q3 loss per share $2.07.  Full Article

Puma Biotechnology secures $100 mln term loan from Silicon Valley Bank and Oxford Finance
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Puma Biotechnology Inc :Puma Biotechnology secures $100 million term loan from Silicon Valley Bank and Oxford Finance.Puma Biotechnology - ‍proceeds from financing will be used to continue to support Nerlynx commercial activities, ongoing research with neratinib ​.  Full Article

Puma Biotech gets EU panel nod for breast cancer drug

June 29 Puma Biotechnology Inc on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.